In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary

NCI Drug Dictionary

  

PEG-proline-interferon alpha-2b 
A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b) protein, in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon subcutaneous administration, IFN-a2b binds to specific interferon cell-surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs); the protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a predominant (90%) positional isomer which allows for further increases in stability and a longer half-life than previous PEG conjugates. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:PEG-P-IFN-alfa-2b
PEG-P-IFN-alpha-2b
pegylated interferon alfa-2b
Code names:AOP2014
P1101